Technologies Transforming the Biomanufacturing Landscape

Translating Technology Innovation to Market Competitiveness

Overall Impact of Biomanufacturing Technology Innovations

Impact on Unmet Needs

Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process development, bio-analytical testing, and regulatory support.

Impact on Capturing Investment Opportunities

As the biologics market is witnessing increased outsourcing of mammalian cell culture activities, a significant expansion of capacity is expected in this area. Biopharma companies will outsource cell line development to specialist vendors, including professional biological contract manufacturing organizations (BioCMOs), or license it from them.

Impact on Technology Implementation

Contract development and manufacturing organizations (CDMOs) need to focus on the attractive opportunity in disposables/single-use bioreactors, improvements in upstream & downstream technologies, advances in lyophilisation & increased application of PAT, continuous bio-manufacturing, new cell culture techniques, and modular facilities/pod manufacturing.

Impact on Strategic Collaborations

CDMOs need to broaden their services to grab emerging opportunities in outsourcing of biologic and biosimilar manufacturing driven by mid and small biotech names. Large BioCDMOs will continue to invest in drug development and clinical manufacturing capabilities through M&A activities.

Impact on Disruptive Business Models

Expanding services of CMOs into the early-stage development of drugs, emergence of virtual biotech, out-licensing, and risk-sharing between pharma and CMOs is disrupting the traditional business models. By offering value-added services to pharma companies, CMOs need to redefine themselves as CDMOs and integrate themselves into the value chain of companies.